Female Infertility
Conditions
Interventions
None listed
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
Female
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Group A: (1) Age 20-50 years old; (2) The normal menstrual cycle of women of childbearing age: 24-35 days; the normal menstrual cycle of perimenopausal women in the past 10 years; (3) Normal BMI range: 18.5-24.9 (WHO standard). 2. Group B: (1) Infertility patients require IVF or ICSI; (2) Have normal bilateral ovaries; (3) Receive IVF/ICSI cycle for the first time; (4) Accept the controlled ovarian stimulation (COS) of r-FSH with the agonist luteal phase short-acting and long-term regimen, with a starting dose of 100 IU-300 IU (the starting dose is adjusted according to AFC, see below for details) or receiving The down-regulation regimen is an antagonist regimen, a fixed dose (150 - 300IU) of r-FSH for controlled ovarian stimulation (COS).
Exclusion criteria
Exclusion criteria: 1. Group A: (1) Pregnancy; (2) According to ultrasound examination, it is found that the developmental abnormalities of the accessory mesonephros such as: congenital absence of vagina (MRKH syndrome); congenital absence of uterus and primordial uterus; naive uterus; unicornuate uterus and residual horn uterus; double uterus and double horns uterus; arcuate uterus; (3) After ultrasound examination, it is found that there are abnormalities of the ovary, such as endometriosis cyst, PCOS, etc; (4) POI patients; (5) Medical history through consultation: endocrine or metabolic abnormalities (ie type I or type II diabetes, or pituitary, adrenal gland, pancreas, thyroid, liver or kidney disease); (6) Medical history through consultation: autoimmune diseases, such as SLE, Sjogrens syndrome, etc; (7) Past history of systemic and pelvic local radiotherapy and chemotherapy; (8) Through consultation, it is found that there is a family genetic history, a history of chromosomal abnormalities, reproductive system tuberculosis, reproductive system tumors and other diseases; (9) Past history of ovarian surgery; (10) The history of hormone therapy in the first 3 months (hormonal contraceptives, gonadotropin releasing hormone [GnRH], FSH); (11) Smoking history; 2. Group B: (1) There are contraindications to the use of r-FSH; (2) Use urinary gonadotropin (HMG); (3) Use clomiphene, letrozole and other micro-stimulation programs that have potential effects on estrogen; (4) Pretreatment with other hormones (growth hormone; contraceptives and androgens, etc.); (5) Have a history of ovarian surgery; (6) History of cytotoxic drugs or pelvic radiotherapy and chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti-Mullerian hormone;Antral Follicle Count;Number of retrieved follicles;Subject operating characteristic curve; | — |
Countries
China
Contacts
Public ContactYingpu Sun
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed